Reykjavik, ICELAND, October 8, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the launch of deCODE BreastCancer™, a new tool for assessing risk of the common forms of breast cancer. For the ...

deCODE Genetics has announced the launch of deCODE T2™, a DNA-based reference laboratory test for the first common and well-validated genetic risk factor for type 2 diabetes (T2D).

The deCODE BreastCancer™ test measures seven widely replicated single-letter variations (SNPs) in the human genome that deCODE and others have linked to risk of breast cancer. These SNPs contribute to ...

The testing of advanced video decoders is a daunting task, considering the greater complexity and nonlinearity of H.264 compared with MPEG-2. Decoding depends on numerous contexts and states that one ...

LONDON, April 15 (Reuters) - The world's first genetic test to assess the risk of individuals developing type 2 diabetes has been launched by Iceland's Decode Genetics Inc. . The biotech company ...

"Through deCODE PrCa (TM), we are bringing together in one tool all of the major genetic risk factors for prostate cancer that we have discovered over the past eighteen months. We believe that ...

REYKJAVIK, Iceland, Oct. 11 deCODE genetics(Nasdaq: DCGN) today announced the launch of deCODE MI(TM), a referencelaboratory test for variations in the genome (called ...

The testing of advanced video decoders is a daunting task, considering the greater complexity and nonlinearity of H.264 compared with MPEG-2. Decoding depends on numerous contexts and states that one ...